Journey Medical Corp (DERM) presents a deeply negative liquidation posture as of March 31, 2026. The MFFAIS-derived cash liquidation value (CLV) is negative $38.8 million, liquid liquidation value (LLV) is negative $9.0 million, and operating liquidation value (OLV) is approximately breakeven at positive $0.6 million. These figures reflect the standard asymmetry under the liquidation lens: intangible assets (product licenses, drug approvals) are zeroed out, while liabilities are held at face value. The company's balance sheet is dominated by intangible assets—FDA-approved dermatology product rights including Emrosi, Qbrexza, and Accutane—which carry zero recovery in liquidation. The primary tangible asset is cash: $27.2 million at March 31, 2026, up from $24.1 million at December 31, 2025, driven by $2.9 million in operating cash flow (a $5.7 million improvement from the prior-year quarter when operations consumed $2.8 million). The primary liability anchor is the SWK Credit Facility with $25.0 million outstanding principal, bearing floating rate interest at 3-month SOFR plus 7.75% (SOFR floor 5%), maturing June 2028. The Third Amendment (September 2025) extended maturity and deferred principal repayment commencement to February 2027. Total SWK obligations including exit fee sum to $32.5 million. Gross-to-net sales accruals totaled $17.3 million at March 31, 2026 (down from $18.7 million at December 31, 2025), reflecting contingent rebate and coupon liabilities that would survive liquidation. The company has disclosed going concern doubt due to recurring losses. Full-year 2025 net loss was $11.4 million; Q1 2026 net loss was $2.2 million, improved from $4.1 million in Q1 2025. The improvement is driven by Emrosi revenue ramp ($6.3 million in Q1 2026 vs. $2.1 million in Q1 2025) offset partially by a $1.3 million non-cash inventory charge related to the 2021 Qbrexza acquisition. No separately tagged XBRL balance-sheet line items were provided in TAG_CONTEXT, so all observations are drawn from the filing narrative and embedded XBRL values in the body. The filing does not separately XBRL-tag the SWK loan balance, intangible asset carrying value, operating lease ROU assets, or gross-to-net accrual liability as standalone XBRL facts in the TAG_CONTEXT supplied—all are referenced in MD&A and footnotes only. The contingent milestone and royalty obligations to license counterparties are expressly disclosed as not quantifiable.
▼ Community Notes